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bstract
High levels of endogenous estrogens are associated with increased risks of breast cancer. Estrogen levels are mainly increased by the activity
f the aromatase enzyme and reduced by oxidative/conjugative metabolic pathways. In this paper, we demonstrate for the first time that catechol
strogen metabolites are potent aromatase inhibitors, thus establishing a link between aromatase activity and the processes involved in estrogen
etabolism. In particular, the anti-aromatase activity of a set of natural hydroxyl and methoxyl estrogen metabolites was investigated using
iochemical methods and subsequently compared with the anti-aromatase potency of estradiol and two reference aromatase inhibitors. Catechol
strogens proved to be strong inhibitors with an anti-aromatase potency two orders of magnitude higher than estradiol. A competitive inhibition
echanism was found for the most potent molecule, 2-hydroxyestradiol (2-OHE2) and a rational model identifying the interaction determinants
f the metabolites with the enzyme is proposed based on ab initio quantum–mechanical calculations. A strong relationship between activity and
lectrostatic properties was found for catechol estrogens. Moreover, our results suggest that natural catechol estrogens may be involved in the
ontrol mechanisms of estrogen production.
2008 Elsevier Ltd. All rights reserved.
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. Introduction
Estrogens are important for the normal development and
rowth of the human body. Besides their involvement in sexual
ifferentiation, control of the reproductive cycle and pregnancy,
hey are implicated in many non-reproductive functions. For
nstance, in the cardiovascular system, estrogens have protec-
ive effects either directly through the interaction with the blood
essels or indirectly through the plasma lipoprotein metabolism
1]. In the bone, estrogens regulate the normal mineraliza-
ion, controlling the balance between bone formation and bone
esorption [2]. In the central nervous system, several neuroen-
ocrine functions have been attributed to estrogens, namely the
europrotection against Alzheimer’s disease and schizophrenia
3].
∗ Corresponding author. Tel.: +351 239859990; fax: +351 239827030.
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However, prolonged exposure to high concentrations of estro-
ens might have detrimental effects. Breast and uterus are highly
ensitive to the mitogenic effects of estrogens and an exces-
ive cell proliferation can lead to replication errors and to an
ncreased risk of breast and endometrial cancer [4].
Estrogens are metabolized by oxidative and conjugative path-
ays. Cytochrome P450 (CYP), a superfamily of metabolizing
nzymes, produces mostly A-ring metabolites, by 2- and 4-
ydroxylation, and D-ring metabolites by 16-hydroxylation
5] (Fig. 1). The catechol metabolites are converted by
atechol-O-methyltransferase (COMT) to their 2-methoxy and
-methoxyestrogen metabolites and subsequently to their glu-
uronide, sulfate and glutathione conjugates. These more soluble
etabolites are found in large amounts in the urine.
Although initially considered inactive, estradiol metabolitesFig. 1) have gained interest in recent years due to the discov-
ry of pro and anticarcinogenic activities and to the elucidation
f their potential to bind to the estrogen receptor and to have
strogenic activity. 2-Hydroxyestradiol (2-OHE2, 6) is the major
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etabolite formed by CYP hydroxylation at the liver and has
uch weaker estrogenic activity than the parent hormone estra-
iol (E2, 1) [6]. 4-Hydroxyestradiol (4-OHE2, 8) is produced
n a minor pathway and has an estrogenic activity similar to
stradiol. Both these catechol estrogens can undergo metabolic
edox cycling with generation of reactive intermediates like
uinones/semiquinones and free radicals which can damage bio-
ogical macromolecules [7]. This mechanism has been pointed
ut to explain the carcinogenic activity of estrogens. Interest-
ngly, in vivo studies have demonstrated that 2-OHE2 does not
nduce tumors, in contrast to 4-OHE2 which is a potent car-
inogen [8]. 2-Hydroxyestrone (2-OHE1, 5) was found to have
ntiestrogenic activity in the hormone-dependent human breast
ancer cell line MCF-7 [9] and 2-methoxyestradiol (2-MeOE2,
t
g
a
tf estrogen conversion paths.
) was found to be antiangiogenic and antiproliferative in several
umor types [10] and almost devoid of estrogenic activity.
In a similar manner to the 4-hydroxyl metabolites, the 16-
ydroxyl estrogens (Fig. 1, compounds 3 and 4) retain strong
ormonal potency [11] and were suggested to increase the risk of
eveloping breast cancer [12,13]. Therefore, despite the oxida-
ive and conjugative metabolism, estrogen derivatives carry out
everal biological activities beyond the estrogenic activity of
stradiol.
Aromatase is the cytochrome P450 enzyme responsible for
he production of estrogens from the corresponding andro-
ens [14]. Recent advances in breast cancer therapy have been
chieved with the use of aromatase inhibitors [15] such as anas-
rozole and letrozole [16,17]. Shimizu et al. showed that natural
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strogens, like estradiol and estrone, are able to bind to the active
ite of the human placental aromatase as competitive inhibitors
18]. These molecules are remarkably different from the known
nhibitors, which makes them attractive because of their poten-
ial for lead optimization towards better therapeutical prospects.
urthermore, since estrogens are produced endogenously, an in
itu mechanism of aromatase activity regulation might occur.
owever, the preliminary study performed by those researchers
as not further extended to the catechol estrogen metabolites
nd their methoxy derivatives.
In this paper, we have focused on the biochemical evalua-
ion of the anti-aromatase potential of a set of natural hydroxyl
nd methoxyl estradiol/estrone metabolites and a related syn-
hetic derivative, the 2-methoxyestradiol-3-methylether (Fig. 4,
ompound 12), using an in vitro assay with aromatase extracted
rom human term placenta. Catechol estrogens proved to be
trong inhibitors with an anti-aromatase potency two orders
f magnitude higher than estradiol. A competitive inhibition
echanism was found for the most potent molecule, 2-OHE2
Fig. 1, compound 6). Furthermore, a rationale for the molecu-
ar interaction is proposed based on ab initio quantum chemical
ethods.
. Materials and methods
.1. Materials
Estradiol, 2-hydroxyestradiol, 2-methoxyestradiol, 2-
ydroxyestradiol-3-methyl ether, 2-methoxyestradiol-3-methyl
ther, 4-hydroxyestradiol, 4-methoxyestradiol, 16-
ydroxyestradiol, estrone, 2-hydroxyestrone, 4-hydroxyestrone
nd 16-hydroxyestrone were purchased from Steraloids, Inc.
London, UK). Formestane, NADPH and dl-aminoglutethimide
ere purchased from Sigma–Aldrich (St. Louis, MO, U.S.A.).
1-3H] Androstenedione (specific activity 25.3 Ci/mmol)
nd the liquid scintillation cocktail Optiphase Hisafe 2 were
urchased from PerkinElmer (Boston, MA, U.S.A.). All the
ther reagents were of adequate grade for biochemical analysis.
.2. Enzymatic preparation
Microsomes from human term placenta were obtained
ccording to the method described by Ryan [19] and were
sed as the source of the enzyme. Briefly, the placenta was
ashed with saline solution, removed from large blood vessels
nd connective tissues, and homogenized in a buffer containing
.05 M sodium phosphate, pH 7.0, 0.25 M sucrose and 0.04 M
icotinamide. Then, a microsomal preparation was isolated by
differential centrifugation procedure with the final centrifuga-
ion at 105,000 × g for 1 h. The microsomes were resuspended in
medium containing 0.1 M sodium phosphate, pH 7.4, 0.25 M
ucrose, 20% glycerol and 0.5 mM dithiothreitol and stored in
liquots at −80 ◦C until needed. All procedures were carried out
t 4 ◦C. No significant loss of activity occurred during the time
equired to complete the assays.
Microsomal protein content was determined by the biuret
ethod using bovine serum albumin as standard.
M
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.3. Concentration–response study
Aromatase activity was measured by quantifying the amount
f 3H2O released when the enzyme converts the tritiated sub-
trate, [1-3H] androstenedione, to the corresponding estrogen.
his method was first described by Siiteri and Thompson [20].
ncubations were performed at 37 ◦C in a medium containing
7 mM sodium phosphate, pH 7.5, [1-3H] androstenedione
6.6 × 105 dpm/24 nM), 15l methanol and 270M NADPH.
he potential inhibitors were dissolved in DMSO and added to
he assay in concentrations ranging from 31.62 to 640 × 103 nM.
he amount of DMSO in the assay was always equal to 2% and
he final incubation volume was 500L. The reaction was started
ith the addition of 30g of microsomal protein and stopped
fter 20 min by adding 1 mL of chloroform and vortexing at
000 rpm for 40 s. After centrifugation at 3000 rpm for 5 min,
he organic phase was discarded and the extraction procedure
as repeated. An aliquot (250L) of the aqueous layer was col-
ected and mixed with 3 mL of liquid scintillation cocktail. The
mount of tritiated water formed in each assay was determined
n a Packard Tri-Carb 2000 CA Liquid Scintillation Analyzer.
ppropriate controls without the compounds in study were per-
ormed in order to determine the maximum enzymatic activity
o which the relative percentage of inhibition was determined.
esults were expressed as mean ± S.E.M. of three independent
ssays, each one in triplicate. Data were treated by nonlinear
egression analysis, using a sigmoidal concentration–response
urve with variable slope. GraphPad Prism software, version
.00 was used for this purpose.
.4. Kinetic analysis
For the kinetic study, similar conditions to the
oncentration–response study were used. The concentra-
ion of [1-3H] androstenedione was varied from 25 to 300 nM,
he concentrations of 2-hydroxyestradiol tested were 500,
000 and 1500 nM and the reaction time was 5 min. An assay
ithout inhibitor was also performed. Results were expressed
s mean ± S.E.M. of at least three independent assays, each
ne in duplicate. Data were fitted by nonlinear regression to the
ichaelis–Menten equation. The kinetic constants, Vmax, Km
nd Ki were estimated by nonlinear curve fitting, and the type of
nhibition was determined from Lineweaver–Burk plots. Graph-
ad Prism software, version 4.00 was used for this purpose.
.5. Electrostatic surface potential calculation details
Three-dimensional models of all molecules were constructed
sing building fragments from the standard libraries of MAE-
TRO 5.1.016 (Schro¨dinger). Initial geometry optimization was
erformed with a conformational search following the Sys-
ematic Unbounded Multiple Minimum (SUMM) [21] routine
mplemented in MACROMODEL 8.1 (Schro¨dinger) with theerck Molecular Force Field (MMFFs) [22] and the Polak-
ibiere Conjugate Gradient (PRCG) minimization method with
n energy convergence criterion of 0.05 kJ/mol. The Generalized
orn equation/surface area (GB/SA) [23] continuum solvation
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Table 1
In vitro aromatase inhibition by estradiol, estrone and derivatives
Compound IC50 (M)a Inhibition at 100M (%)
E2 (1) 227 ± 8.3 35
E1 (2) 36 ± 1.0 47
16-OHE1 (3) NDb 9
E3 (4) NDb 8
2-OHE1 (5) 2.4 ± 0.06 94
2-OHE2 (6) 1.1 ± 0.03 95
4-OHE1 (7) 1.8 ± 0.05 96
4-OHE2 (8) 2.6 ± 0.09 92
2-MeOE2 (9) 296 ± 10.2 33
4-MeOE2 (10) NDb 14c
2-OHE2,3Me (11) 134 ± 1.8 41
2-MeOE2,3Me (12) 234 ± 3.0 21
Aminoglutethimide 10 ± 0.09 92
Formestane 0.092 ± 0.004 NDb
a Results are shown as the mean ± S.E.M. of three independent assays, each
one in triplicate.
b ND: not determined.
c Percentage of inhibition at 31.62M.
-8 -7 -6 -5 -4 -3
0
10
20
30
40
50
60
70
80
90
100
Log [I] (M)
A
ro
m
at
as
e 
ac
ti
vi
ty
 (
%
 o
f 
co
n
tr
o
l)
Fig. 2. Concentration–response curves obtained with 4-OHE1 (7) (), 2-
OHE2,3Me (11) (), 2-MeOE2,3Me (12) () and 16-OHE1 (3) () tested
as aromatase inhibitors. Aminoglutethimide (♦) was tested as a reference aro-
matase inhibitor. Each point represent the mean of three independent assays
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odel was used with parameters for water, with a dielectric con-
tant ε of 78. The molecular mechanics geometry was further
ptimized with Gaussian 98 (Gaussian, Inc.) [24] at the semi-
mpirical Austin Model 1 (AM1) level and the electron density
istribution for electrostatic surface potential (ESP) calculation
as calculated at the HF/6-31G* level.
. Results
.1. Concentration–response study
Inhibition of the human placental aromatase by estradiol (E2,
), estrone (E1, 2), their physiological metabolites 16-OHE1
3), E3 (4), 2-OHE1 (5), 2-OHE2 (6), 4-OHE1 (7), 4-OHE2 (8)
-MeOE2 (9), 4-MeOE2 (10), 2-OHE2,3Me (11) (Fig. 1), and
he related synthetic derivative 2-MeOE2,3Me (12), was eval-
ated using an in vitro radiometric assay. Briefly, the use of a
adiolabeled androgen as the substrate of the enzyme allowed a
imple and rigorous quantification of the extent of the aromati-
ation reaction which is proportional to the amount of tritiated
ater formed together with the corresponding estrogen. Full
oncentration–response curves were obtained by evaluation of
he aromatase activity in the presence of the potential inhibitors
ith the maximal activity being given by control experiments
i.e. experiments without the compounds in study). A broad
ange of inhibitor concentrations to allow the determination
f the half maximal inhibitory concentrations (IC50) was used.
n the case of less active compounds, low solubility at higher
oncentrations did not allow the establishment of a complete
oncentration–response curve. The IC50 and the percentage of
romatase inhibition at 100M for the complete set of estro-
ens tested are shown in Table 1. The most active estrogens,
-OHE1 (5), 2-OHE2 (6), 4-OHE1 (7) and 4-OHE2 (8) inhib-
ted the aromatase enzyme with remarkable potency, showing a
lear sigmoidal concentration–response behavior, as represented
or compound 7 in Fig. 2. The observed potency is stronger
han for the reference non-steroid first generation aromatase
nhibitor tested, aminoglutethimide. In contrast, E2 (1), E1 (2)
nd their methoxy- and 16-hydroxy derivatives showed lower
nti-aromatase potency, as evidenced in Fig. 2 for 2-OHE2,3Me
12) and 16-OHE1 (3). However, all the compounds in study
resented a lower potency than formestane, a second generation
teroid aromatase inhibitor, also used as a reference inhibitor
Table 1).
.2. Kinetic analysisA more detailed analysis on 2-OHE2 (6), the most potent
ompound under study (lowest IC50), showed a mechanism of
ompetitive inhibition, as displayed in the Lineweaver–Burk plot
t
d
fi
(
able 2
inetic constants (Ki, Km and Vmax), relative inhibitory potency (Ki/Km) and type of
ompound Ki (M)a Km (M) V
-OHE2 (6) 1.6 ± 0.03 0.14 ± 0.002 7
a Result is shown as the mean ± S.E.M. of three independent assays, each one in duerformed in triplicate and the vertical bars the standard error of the mean
S.E.M.). The data were analyzed by nonlinear regression analysis using a
igmoidal concentration–response curve with variable slope.
Fig. 3). Experiments were performed with several concentra-
ions of substrate in the absence and in the presence of three
ifferent concentrations of 2-OHE2 (6). The data obtained were
tted by nonlinear regression to the Michaelis–Menten equation
Fig. 3, inset) and the kinetic constants are shown in Table 2.
aromatase inhibition by 2-OHE2
max (pmol/min/mg protein) Ki/Km Inhibition
0 ± 0.5 11 Competitive
plicate.
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Fig. 3. Lineweaver–Burk plot of the inhibition of human placental aromatase by
2-OHE2 (6). A control () and three increasing inhibitor concentrations were
used: 0.5M (), 1.0M () and 1.5M (). A Michaelis–Menten plot of
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ehe same data is shown in the inset. Each point represents the mean of three
ndependent assays performed in duplicate and the vertical bars, the standard
rror of the mean (S.E.M.).
.3. Electrostatic surface potential calculation
Further understanding of the possible molecular recognition
eterminants leading to the binding of these catechol inhibitors
o the active site of the aromatase, was pursued using ab ini-
io quantum chemistry methods. Six representative compounds,
ncluding the best inhibitor found in this study (2-OHE2, 6),
nd five other related compounds, the estradiol precursor E2
1), the 4-OHE2 (8), a methoxy metabolite (2-MeOE2, 9), the
-MeOE2,3Me (12) and a 16-hydroxyl derivative (E3, 4), were
epresented in a three dimensional model with optimized geome-
ry. The electrostatic potential derived from ab initio calculations
t the Hartree–Fock theory level, along with the standard polar-
zed ζ basis set (HF/6-31G*), mapped onto the electron density
sosurface, is shown in Fig. 4. As expected, catechol estrogens,
c
g
t
(
ig. 4. Electrostatic surface potential (ESP) mapped on the 0.02 e/A3 electron dens
-OHE2 (6), 4-OHE2 (8), 2-MeOE2 (9) and 2-MeOE2,3Me (12) are displayed from
lectron density contour. ESP ranges from V = 0.1 eV (blue) to V = −0.1 eV (red).try & Molecular Biology 110 (2008) 10–17
.e. 2-OHE2 (6) and 4-OHE2 (8) have a strong negative electro-
tatic potential centered at each catechol oxygen atom, and are
artially stabilized through an intramolecular hydrogen-bond.
o steric hindrance limits the catechol access to a macromolec-
lar target, therefore, intermolecular charge-transfer interactions
ight occur at the active site of the aromatase, either by hydrogen
onding or metal coordination, which might explain the strong
nti-aromatase potency. Similar regions of negative electrostatic
otentials are found in 2-MeOE2 (9), however, substitution of the
2 hydroxyl by a methoxy group introduces sterical hindrance
t the ring A and may limit the interaction with the enzyme,
hich might be responsible for the low anti-aromatase activ-
ty of 2-MeOE2 (9). In a similar manner, 2-MeOE2,3Me (12),
double methoxylated derivative, will fail to establish strong
lectrostatic interactions with the active site of the aromatase.
n the other hand, E2 (1) and E3 (4), show a different ESP, with
single negative potential area derived from the 3-hydroxyl at
he ring A.
Electrostatic potential similarities between the two most
ctive estrogens, 2-OHE2 (6) and 4-OHE2 (8), are clearly evi-
ent at the isosurface potential contour, represented in Fig. 5.
he negative potential at ring A of both catechols is remark-
bly superimposable, either considering its spatial location or
he intensity, suggesting a common binding mode, guided by
trong electrostatic interactions.
. Discussion
The biochemical evaluation of the main estradiol and estrone
etabolites revealed that the catechol estrogens 2-OHE1 (5), 2-
HE2 (6), 4-OHE1 (7) and 4-OHE2 (8) are potent aromatase
nhibitors with half maximal inhibitory concentrations in the
ange of 1.1–2.6M (Table 1). In our assay conditions, E2
1) showed anti-aromatase activity, though only at higher con-
entrations (IC50 = 227M). The substitution of one hydroxyl
roup at the catechol moiety by methoxy markedly decreased
he anti-aromatase activity. In a similar manner, 2-MeOE2,3Me
12), a 2,3-dimethoxy synthetic derivative, showed reduced
ity isocontour derived from ab initio HF/6-31G* calculations. E2 (1), E3 (4),
the -face as shown by the transparent capped-stick model on the inside of the
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3 (4), 2-OHE2 (6), 2-MeOE2 (9) and 2-MeOE2,3Me (12) are displayed from
ontour. 4-OHE2 (8) is displayed from the -face. Arrows indicate similarities
nti-aromatase potency. Moreover, the 16-hydroxylation, leads
o weak aromatase inhibitors with only 8–9% inhibition at a
00M concentration, as seen for E3 (4) and 16-OHE1 (3).
In particular, the anti-aromatase activity of 2-OHE2 (6), the
ost potent inhibitor tested, was found to be ca. 200 times
tronger than E2 (1). This molecule competed with androstene-
ione for the active site of the enzyme showing a typical
ompetitive Lineweaver–Burk plot (Fig. 3) and a good rela-
ive potency of aromatase inhibition (Ki/Km = 11). These results
re in agreement with the type of inhibition found for estra-
iol and estrone [18] and demonstrate for the first time that
strogens metabolized to catechol derivatives have an increased
nti-aromatase potential.
Steric and electronic effects are expected to control the recog-
ition and binding affinity of these molecules to the active site
f aromatase. Catechol estrogens have in common a pair of
ydroxyl groups prone to interact with the aromatase active
ite, either at C2 and C3, in compounds 5 and 6 or at C3 and
4 in compounds 7 and 8. Large differences in anti-aromatase
otency between catechols and the other estrogens in study
uggest that catechol hydroxyls are involved in strong elec-
rostatic interactions, like hydrogen bonds, either as donors
r as acceptors, or in coordination with the heme iron at
he aromatase active site. Methoxylation of one or both A-
ing hydroxyl groups strongly blocks the accessibility to the
nzyme and prevents the establishment of favorable interac-
ions. No relationships between anti-aromatase activity and
he oxidation state at C-17, either hydroxyl or ketone, were
ound.
c
g
c
cs at isosurface values of V = 0.025 eV (blue) and V = −0.025 eV (red). E2 (1),
face as shown by the transparent capped-stick model on the inside of the ESP
negative potential contour of the most active compounds.
Human breast tissue is a major source of estrogen production
n post-menopausal women. Breast cells contain steroidogenic
nzymes essential to estrogen production, as well as estrogen
etabolizing enzymes [25–27]. 2-OHE2 (6) is produced mainly
y CYP1A1, CYP1A2 and CYP3A4, whereas 4-OHE2 (8) is
roduced mostly by the CYP1B1 [28]. Genetic polymorphisms
f several estrogen metabolizing enzymes have been identified
29]. Different variant alleles of CYP1A1 and CYP1B1 deter-
ine changes in the ratio of 2-/4-hydroxy formation and these
ifferences have been correlated with post-menopausal breast
ancer risk [27]. In particular, catechol estrogens seem to play
dual role on the initiation of breast tumors: while 2-hydroxy
erivatives have preventive effect due to their anti-estrogenic
nd antiproliferative activities in hormone-dependent human
reast cancer cells [9,30], 4-hydroxy derivatives may act as
umor initiators due to a significative estrogenic activity [6] and
he formation of 3,4-quinones, electrophilic intermediates that
ovalently bind to DNA and form depurinating adducts [31,32].
Although plasma levels of estrogen metabolites are low, these
oncentrations do not reflect the local concentrations. Indeed,
igh levels of catechol estrogens were detected in both normal
nd breast cancer tissue samples. Castagnetta et al. [33] reported
concentration of catechol estrogens 50 times higher than those
f E1 and E2, suggesting that oxidative metabolism in the breast
issue is very effective. On the other hand, androstenedione con-
entration in tumor breast tissue was found to be ca. 10 times
reater than the estradiol levels [34,35]. Therefore, catechol
oncentrations might be greater than the levels of androgens,
ompeting to the active site of the aromatase.
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COMT is the major enzyme in catechol biotransformation.
inetic analysis of this enzyme in the presence of catechol estro-
ens, has revealed higher catalytic efficiency for the formation of
4-methoxy estrogens than C2-methoxy estrogens and Km val-
es are the range of 24–108M [36]. Considering these data and
he low Ki (1.6M) found by us for 2-OHE2 (6), we can spec-
late that estrogens are stable enough to inhibit the aromatase
nzyme. Thus, the results of our study suggest that the oxidative
etabolism of estrogens in the breast might be responsible for an
ntracrine control mechanism of the aromatase activity exerted
y catechol estrogens. In particular the 2-OHE2 (6) which is
on carcinogenic in vivo and almost devoid of estrogenic activ-
ty [6], might offer protection against excessive production of
strogens in post-menopausal women, and consequently against
reast cancer. So, the effectiveness of this mechanism of com-
etitive inhibition will depend on the in situ concentrations of
strogen catechols and androgens, and on the metabolic stability
f the catechols.
Moreover, the strongest anti-aromatase activity found in the
resent work for the 2-OHE2 (6), suggests that a shift towards
he 2-hydroxylation pathway might determine some long-term
rotection against breast cancer by a biochemical mechanism of
ompetitive inhibition of the enzyme aromatase. Furthermore,
-MeOE2 (9), the product of 2-OHE2 (6), methoxylation by
OMT is a potent antiangiogenic and antiproliferative com-
ound, already in clinical trials [10].
The reduced oral bioavailability of catechol estrogens due to
ethylation by COMT and the potential to undergo metabolic
edox cycling with generation of free radicals and reactive
emiquinone/quinone derivatives limits the use of catechol estro-
ens as therapeutical agents to the endocrine treatment of breast
ancer. Further studies based on the chemical physical results
btained here should therefore be performed in order to find
ppropriate bioisosteric derivatives, devoid of estrogenic activity
r having anti-estrogenic activity, with improved pharmacoki-
etics and reduced toxicity.
In summary, we have demonstrated that natural catechol
strogens have strong anti-aromatase activity and might be
esponsible for an intracrine control mechanism of estrogen pro-
uction in post-menopausal women. With our study, important
olecular recognition determinants have been calculated and
rom this integrated approach, structure–activity rules have been
ationalized which can be used for the lead optimization of new
romatase inhibitors.
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